AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05711394
Drug: Atogepant
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05711394
Drug: Placebo-Matching Atogepant
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06434519
Drug: Metronidazole cream
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After application of one of the moisturizers under investigation in this study to the right side of the patient's face, x5 tape strips will be collected from the left side of a patient's face. These will provide negative controls for quantitation of metronidazole in the stratum corneum. Then, 0.5 mL of a 1% metronidazole cream will be applied to both the right and left sides of a patient's face with clean gloves to prevent cross contamination. Tapes strips x5 will subsequently be collected from the left and right sides of the face at 1 hour and 4 hour time points to assess penetrance of metronidazole through the stratum corneum.
Trial: NCT04748601
Drug: Qudexy XR
RxNorm normalized name: Qudexy XR Sprinkle
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Extended-Release Capsule
Trial: NCT05303987
Drug: Propofol sedation
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given.
Trial: NCT05303987
Drug: Dexmedetomidine sedation
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given.
Trial: NCT05567315
Drug: local anaesthetic injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
Trial: NCT04839224
Drug: carbogen
RxNorm normalized name: carbogen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
Trial: NCT04839224
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Trial: NCT05934942
Drug: BI 1358894
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1358894
Trial: NCT05552339
Drug: Finerenone (Kerendia, BAY94-8862)
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Following the physicians' decision.
Trial: NCT05552339
Drug: Type 2 DM drugs
RxNorm normalized name: alpha-amylase A type 1-2
DrugBank: Amyl acetate (DB15927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the physicians' decision
Trial: NCT06315205
Drug: Letrozole LEBE 75 mg
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg
Trial: NCT06315205
Drug: Letrozole LEBE 150 mg
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg
Trial: NCT06315205
Drug: Letrozole LEBE 225 mg
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
Trial: NCT05645757
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics
Trial: NCT05645757
Drug: WCK 6777
RxNorm normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of ertapenem (ERT) and zidebactam (ZID)
Trial: NCT05645757
Drug: Zidebactam
RxNorm normalized name: Zidebactam
DrugBank: Zidebactam (DB13090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class
Trial: NCT05687123
Drug: Lutetium Lu 177 Dotatate
RxNorm normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05687123
Drug: Sunitinib Malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04973605
Drug: Sonrotoclax
RxNorm normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally daily
Trial: NCT04973605
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once weekly either orally or intravenously
Trial: NCT04973605
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously weekly
Trial: NCT04973605
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously weekly
Trial: NCT04973605
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally daily
Trial: NCT06550609
Drug: Miltefosine Oral Capsule
RxNorm normalized name: miltefosine Oral Capsule
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
Trial: NCT04971031
Drug: Reproxalap Ophthalmic Solution (0.25%)
RxNorm normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
Trial: NCT04971031
Drug: Vehicle Ophthalmic Solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
Trial: NCT05824091
Drug: MK-7762 (TBD09)
RxNorm normalized name: vitamin MK 7
DrugBank: MK-7622 (DB12897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
Trial: NCT06559826
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following screening and baseline assessments, individuals randomized to KAP will undergo a preparatory session prior to the first day of dosing. Participants will complete a sequence of four to five intramuscular (IM) ketamine assisted therapy sessions.
Trial: NCT06507371
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w
Trial: NCT06507371
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin: 130mg/m2 d1 q3w
Trial: NCT05726864
Drug: ELI-002 7P
RxNorm normalized name: eli-cel
DrugBank: Elivaldogene autotemcel (DB16746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
Trial: NCT05188170
Drug: Niclosamide
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
Trial: NCT06186700
Drug: Pentoxifylline 400mg plus chemotherapy
RxNorm normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will take 400 mg tablets of Pentoxifylline, 3 tablets per day, starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the cycles of neoadjuvant chemotherapy comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel or dose-dense paclitaxel.
Trial: NCT05293028
Drug: F527
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
Trial: NCT05943665
Drug: MDMA
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication and therapy combined
Trial: NCT04903678
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan is performed for intrathecal chemotherapy
Trial: NCT04735393
Drug: Reproxalap Ophthalmic Solution (0.25%)
RxNorm normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
Trial: NCT04735393
Drug: Reproxalap Ophthalmic Solution (0.25%)
RxNorm normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
Trial: NCT06238622
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550
Trial: NCT05218889
Drug: surufatinib + camrelizumab + nab-paclitaxel + S-1
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1
Trial: NCT05218889
Drug: nab-paclitaxel + gemcitabine
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
Trial: NCT06035874
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patient willl be randomized 1:1 in both the arms
Trial: NCT06140524
Drug: Linvoseltamab
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous (IV) infusion
Trial: NCT05852431
Drug: Pegozafermin
RxNorm normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05749822
Drug: Fenofibrate 200mg
RxNorm normalized name: FENOFIBRATE 200MG CAP
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200mg/day
Trial: NCT05749822
Drug: UDCA
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 13-15mg/kg/day
Trial: NCT05016349
Drug: All trans-retinoic acid
RxNorm normalized name: all trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
Trial: NCT05016349
Drug: 13-Cis Retinoic Acid plus Tocopherol
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
Trial: NCT05016349
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone 200mg capsules daily for 28 days
Trial: NCT05016349
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Liquid taken orally for daily for 28 days
Trial: NCT05016349
Drug: 9 cis retinoic acid
RxNorm normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
Trial: NCT05016349
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
Trial: NCT04862377
Drug: Poractant Alfa Intratracheal Suspension [Curosurf]
RxNorm normalized name: poractant alfa Intratracheal Suspension [Curosurf]
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg.
Trial: NCT04862377
Drug: Budesonide 0.5 MG/ML
RxNorm normalized name: budesonide 0.5 MG/ML
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide.
Trial: NCT04816097
Drug: Dexamethasone phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 doses of dexamethasone 6mg IM 48h before elective CS.
Trial: NCT00005017
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00005017
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00005017
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00005017
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005017
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00005017
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05034562
Drug: Gallium Ga 68-labeled PSMA-11
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00000654
Drug: Fialuridine
RxNorm normalized name: Fialuridine
DrugBank: Fialuridine (DB15427)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04663126
Drug: Tc-99m tilmanocept
RxNorm normalized name: TECHNETIUM TC-99M TILMANOCEPT
DrugBank: Technetium Tc-99m tilmanocept (DB09266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
Trial: NCT04582266
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
Trial: NCT06239467
Drug: OKI-219
RxNorm normalized name: OKI-179
DrugBank: OKI-179 (DB17583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral twice daily
Trial: NCT06239467
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular injection
Trial: NCT06239467
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV)
Trial: NCT05430152
Drug: Low-Dose Naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug dosing schedule (LDN):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)
Trial: NCT05485779
Drug: AQ280
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral
Trial: NCT05583552
Drug: Imetelstat sodium
RxNorm normalized name: imetelstat sodium
DrugBank: Imetelstat (DB14909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT06087588
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PENG sham block with 20ml 0,9% normal saline
Trial: NCT06087588
Drug: 95% ethanol
RxNorm normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PENG neurolysis with 2.5ml of 95% ethanol
Trial: NCT06342986
Drug: FT536
RxNorm normalized name: Fluticasone Terephthalate 536
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.
Trial: NCT06342986
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.
Trial: NCT05965193
Drug: Intravenous thrombolysis(rt-PA)
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
Trial: NCT05253131
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer.
Trial: NCT05170256
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
Trial: NCT06232694
Drug: Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Phase Regimen
Trial: NCT06232694
Drug: Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Consolidation therapy after remission
Trial: NCT04610970
Drug: TQ-B3525 tablets
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Trial: NCT02211222
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
Trial: NCT00000702
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no